Lessons from Recent Cardiovascular Outcome Trials of Type 2 Diabetes.
- Author:
Nam Hoon KIM
1
;
Sin Gon KIM
Author Information
- Publication Type:Randomized Controlled Trial ; Review
- Keywords: Cardiovascular disease; Diabetes mellitus; Randomized controlled trial; Type 2
- MeSH: Cardiovascular Diseases; Diabetes Mellitus; Hypoglycemic Agents; Licensure; United States Food and Drug Administration
- From:Journal of Korean Diabetes 2017;18(1):7-13
- CountryRepublic of Korea
- Language:Korean
- Abstract: Since the US Food and Drug Administration issued guidance requiring cardiovascular safety for all antidiabetic drugs in 2008 (US FDA industry guidance for licensing of antidiabetic drugs), the number of cardiovascular outcome trials in diabetes has remarkably increased. Cardiovascular outcome trial is considered a gold standard for establishing the cardiovascular safety of antidiabetic agents. However, there are possible limitations in information gained from cardiovascular outcome trials and other issues such as cost. In this review, we summarize recent cardiovascular outcome trials in type 2 diabetes and provide an overview of the implications and limitations of those trials.
